Repatha (Evolocumab) for Children Under 12: A Complete Caregiver Administration Guide

What Is Repatha and Why Would a Child Under 12 Need It?

Repatha (evolocumab) is a monoclonal antibody that blocks PCSK9, a protein that normally degrades LDL receptors on liver cells. By blocking PCSK9, Repatha keeps more LDL receptors active so the liver clears more LDL-C from the bloodstream. In adults, the FOURIER trial showed evolocumab reduced LDL-C by a mean of 59% and cut major cardiovascular events by 15% over roughly 2.2 years. Children need this drug for a different but related reason.

Familial hypercholesterolemia (FH) is a genetic condition caused by mutations in the LDL receptor gene, the APOB gene, or the PCSK9 gene itself. Heterozygous FH (HeFH) affects approximately 1 in 250 people worldwide, making it one of the most common inherited metabolic disorders. Children with untreated HeFH accumulate LDL-C from birth, and atherosclerotic plaques can begin forming in childhood. Getting LDL-C under control early is not optional for these children.

The FDA approved evolocumab for pediatric HeFH in children aged 10 and older in 2021, based on the HAUSER-RCT study. In HAUSER-RCT, 157 children aged 10 to 17 with HeFH received evolocumab or placebo on top of existing lipid-lowering therapy. After 24 weeks, evolocumab reduced LDL-C by a mean of 38.3 percentage points more than placebo. That is a large, clinically meaningful reduction in a population where every decade of excess LDL-C exposure increases lifetime cardiovascular risk.

Why the Under-10 Age Gap Matters

No randomized trial data supports evolocumab in children under 10. The drug's FDA label does not authorize use below age 10 for HeFH. If a clinician prescribes it off-label for a younger child with homozygous FH or another severe dyslipidemia, that decision rests on adult pharmacokinetic extrapolation and case-level clinical judgment, not a dedicated pediatric study. Ask the prescribing physician specifically what data supports use in your child's age group.

The Family Connection for Female Caregivers

Because FH is autosomal dominant, there is roughly a 50% chance that a mother of an affected child also carries an FH mutation. If you are administering Repatha to your child and have not had your own lipid panel and genetic counseling reviewed, consider asking your own doctor whether you qualify for a PCSK9 inhibitor. ACOG recommends cardiovascular risk assessment as part of well-woman care, and FH is explicitly within that scope.

Approved Doses for Pediatric HeFH (Ages 10 and Older)

Two dosing schedules are supported by the FDA label for HeFH in children 10 and older. The treating physician will select one based on convenience, adherence, and the child's response.

Every-Two-Week Dosing

140 mg subcutaneously every two weeks, given as a single injection using the SureClick autoinjector or the prefilled syringe. This schedule produces steadier drug exposure across the month and may suit families who find a predictable biweekly calendar easier to maintain.

Once-Monthly Dosing

420 mg subcutaneously once a month, given as three consecutive 140 mg injections (using SureClick or prefilled syringe) or as a single administration via the Pushtronex on-body infusor over approximately nine minutes. The FDA label states that if using three injections, all three should be given consecutively within 30 minutes at different injection sites.

Injection Sites

Recommended sites are the abdomen (at least 2 inches from the navel), the upper outer thigh, and the upper outer arm. Rotate sites with each injection. Never inject into skin that is bruised, tender, scarred, or has stretch marks. In younger or smaller children, the abdomen or thigh is often easier to access than the upper arm.

Step-by-Step Caregiver Injection Guide

Giving a subcutaneous injection to a child for the first time feels daunting. Most caregivers become comfortable within two or three administrations. Read this section alongside the manufacturer's Instructions for Use, and ask the prescribing pharmacist or nurse to do a hands-on demonstration before the first home injection.

Before You Start

1. Wash your hands thoroughly with soap and water for at least 20 seconds.
2. Remove the Repatha device from the refrigerator and allow it to reach room temperature. The SureClick autoinjector needs at least 30 minutes; the prefilled syringe needs at least 45 minutes. Do not microwave, run under hot water, or shake to speed warming. Cold injections cause more discomfort and may affect drug dispersion in the subcutaneous tissue.
3. Inspect the solution through the viewing window. It should be clear to opalescent (slightly cloudy), colorless to pale yellow. Do not use it if it contains visible particles, is discolored, or if the device appears damaged.
4. Gather supplies: alcohol wipes, a puncture-resistant sharps container, a cotton ball or gauze, and a small bandage if your child tends to bleed at injection sites.

SureClick Autoinjector: Step by Step

The SureClick is a push-and-hold device. The needle is hidden before and after use, which reduces anxiety for children.

1. Remove the orange cap by pulling it straight off. Do not replace the cap after removal.
2. Place the yellow safety guard flat and firm against the chosen injection site. The device should form a 90-degree angle with the skin.
3. Press down firmly until you hear the first click. This triggers the needle insertion and drug delivery.
4. Keep pressing and hold in place until you hear the second click, then count three more seconds before lifting the device. The second click means the injection is complete; the three-second hold ensures full dose delivery.
5. Lift the device straight up. The orange needle guard should extend automatically. If it does not retract or the inspection window shows the plunger has not moved fully, contact the pharmacy.
6. Dispose of the device immediately in the sharps container.

Prefilled Syringe: Step by Step

The prefilled syringe gives caregivers slightly more control over injection speed, which some children prefer.

1. Remove the needle cap by pulling straight. Do not twist.
2. Pinch a fold of skin at the injection site between your thumb and forefinger. This lifts subcutaneous tissue away from muscle.
3. Insert the needle at a 45- to 90-degree angle. In children with less subcutaneous tissue, a 45-degree angle reduces the risk of intramuscular injection.
4. Push the plunger slowly and steadily until the barrel is empty.
5. Release the skin fold, then withdraw the needle at the same angle you inserted it.
6. Apply gentle pressure with a cotton ball. Do not rub, as rubbing can cause bruising and may redistribute the drug away from the intended depot site.
7. Activate the needle safety device per the Instructions for Use before disposing in the sharps container.

Pushtronex On-Body Infusor (420 mg, Monthly)

The Pushtronex is a wearable infusor that adheres to the skin and delivers the full 420 mg dose over about nine minutes without a caregiver holding a device in place. It may be a better option for children who are anxious about conventional injections or who have limited injection-site tissue.

The device is applied to the abdomen or thigh, activated by pressing a button, and removed after the green indicator confirms completion. A trained pharmacist or nurse should demonstrate application before first home use. The manufacturer's full Instructions for Use detail body-position requirements and error indicators.

Storage, Handling, and Disposal

Proper storage protects drug potency and child safety.

• Refrigerator storage: Keep Repatha at 36°F to 46°F (2°C to 8°C) in the original carton to protect from light.
• Room-temperature storage: If refrigeration is temporarily unavailable (travel, power outage), the drug may be stored at room temperature up to 77°F (25°C) for up to 30 days. After 30 days at room temperature, discard unused devices even if they appear intact.
• Never freeze: Freezing damages the antibody structure. If a device has been frozen, discard it.
• Keep out of direct sunlight and heat sources.
• Sharps disposal: Use an FDA-cleared sharps disposal container. Many pharmacies offer free containers. When the container is about three-quarters full, seal and dispose of it according to your state or local guidelines. FDA guidance on safe sharps disposal applies broadly to all injectable medications.

Missed Doses and Schedule Adjustments

Missing an injection is not automatically harmful, but it should be addressed quickly.

• Every-two-week schedule: If a dose is missed and the next scheduled dose is more than 7 days away, give the missed dose as soon as possible. If fewer than 7 days remain until the next scheduled dose, skip the missed dose and resume the usual schedule.
• Monthly schedule: If a dose is missed and the next scheduled dose is more than 7 days away, give the missed dose as soon as possible. Then resume the original monthly schedule from that new administration date.

Do not double-dose. Contact the prescribing physician or pharmacist if you are unsure how to recalculate the schedule after a missed dose.

Common Side Effects in Pediatric Patients and How to Manage Them

The HAUSER-RCT trial reported that evolocumab was well tolerated in children aged 10 to 17, with a safety profile similar to adults. The most commonly reported adverse effects were:

• Injection-site reactions: Redness, bruising, pain, or swelling at the injection site. These occurred in roughly 5% to 7% of pediatric participants in HAUSER-RCT. Applying a cold pack to the site for 30 seconds before injection and ensuring the drug is fully at room temperature before administration both reduce discomfort.
• Nasopharyngitis and upper respiratory infections: Common in the pediatric age group regardless of drug exposure; no higher rate than placebo in HAUSER-RCT.
• Influenza-like symptoms: Mild, transient.
• Back pain and fatigue: Reported rarely.

Serious adverse events were uncommon and did not differ significantly from placebo in the trial. There are no established neurocognitive safety signals specific to pediatric patients from evolocumab, though the adult FOURIER-OLE extension study found no adverse effect of evolocumab on cognitive function over a median of 5 years.

When to Call the Doctor Immediately

Call the prescribing physician or go to urgent care if your child develops:

• Signs of a serious allergic reaction: hives, facial swelling, difficulty breathing, or a rash that spreads rapidly.
• Severe injection-site reaction that does not improve within 48 hours.
• Unexplained muscle weakness or pain (rare, but worth reporting given the lipid-lowering drug class).

Pregnancy, Lactation, and Contraception: What Female Caregivers Need to Know

This section addresses two distinct situations: a female caregiver who is pregnant or breastfeeding and is administering Repatha to a child, and a woman who takes Repatha herself and becomes pregnant or wishes to breastfeed.

Evolocumab in Pregnancy: Human Data Is Absent

There are no adequate and well-controlled studies of evolocumab in pregnant women. Animal reproductive studies using doses up to 12 times the maximum recommended human dose showed no direct fetal harm in cynomolgus monkeys during organogenesis. However, IgG antibodies cross the placenta, and evolocumab is an IgG2 monoclonal antibody. Placental transfer increases across the second and third trimesters as FcRn receptors become more active. This means fetal exposure is possible, even though the clinical consequences in humans are unknown.

The FDA label states that evolocumab should be used during pregnancy only if the potential benefit justifies the potential risk. Lipid levels change substantially during pregnancy; total cholesterol and LDL-C rise physiologically starting in the second trimester, so the decision to continue or pause a PCSK9 inhibitor during pregnancy requires individual risk-benefit discussion with a cardiologist, maternal-fetal medicine specialist, or lipid specialist.

For a pregnant woman administering this drug to a child: Handling a prefilled syringe or autoinjector does not constitute meaningful exposure risk. The drug is not absorbed through intact skin. Standard precautions (washing hands after handling any injectable medication) are sufficient. There is no contraindication to a pregnant caregiver administering Repatha injections.

Lactation

No data exist on the presence of evolocumab in human breast milk, its effects on the breastfed infant, or its effects on milk production. IgG antibodies are present in breast milk at low levels, and the oral bioavailability of large-molecule monoclonal antibodies in infants is expected to be negligible due to GI proteolysis. The LactMed database at NCBI should be consulted for any updates. A woman who is breastfeeding and considering starting evolocumab for her own FH should discuss the timing and risk with her physician. Current guidance does not provide a clear recommendation, and the decision is individualized.

Contraception for Women Taking Evolocumab

Evolocumab is not classified as a teratogen in the way that statins are. Statins are contraindicated in pregnancy and carry a requirement for reliable contraception in women of reproductive age. Evolocumab does not carry a formal contraception requirement in its FDA label, but given the absence of human pregnancy safety data, women of reproductive age taking evolocumab for their own FH should discuss family planning with their prescriber, particularly around the timing of conception.

Perimenopause and Post-Menopause: A Life-Stage Note

LDL-C rises significantly after menopause due to the loss of estrogen's upregulating effect on hepatic LDL receptors. A woman who is post-menopausal and managing her own FH may find that her LDL-C becomes harder to control with statins alone during or after the menopause transition. The Menopause Society acknowledges cardiovascular risk as a leading health concern for post-menopausal women. PCSK9 inhibitors including evolocumab are a reasonable escalation option in this life stage, and the FOURIER trial enrolled women who were included in the 15% cardiovascular event reduction finding, though women made up only about 25% of the trial population, an evidence gap worth acknowledging.

Who This Is Right For and Who Should Use Caution

Children Who Fit the Approved Use

• Age 10 or older with confirmed HeFH (genetic testing or clinical diagnosis by a lipid specialist).
• Already receiving maximally tolerated statin therapy (with or without ezetimibe) and LDL-C remains above goal.
• A caregiver who is trained and comfortable with subcutaneous injection technique or willing to be trained.
• Access to reliable refrigeration for storage.

Children and Families Who Need Extra Discussion First

• Children under 10 years: use is off-label; the risk-benefit discussion must be explicit.
• Children with homozygous FH (HoFH): evolocumab is approved for adults with HoFH but pediatric HoFH data are limited. The family should be referred to a specialized lipid center.
• Families without stable refrigeration access at home or during frequent travel. The 30-day room-temperature window helps but has limits.
• Children with needle phobia: the Pushtronex infusor or a referral for behavioral support may be appropriate before starting.
• Mothers who are pregnant and considering starting their own evolocumab therapy: defer to specialist guidance until after delivery or weaning.

Monitoring After Starting Repatha in a Child

Once Repatha is started, monitoring is not as intensive as with statins, but it is not absent either.

• Lipid panel: Obtain fasting lipids 4 to 12 weeks after initiation and after any dose adjustment to confirm response. The goal LDL-C for children with HeFH is generally below 130 mg/dL, or below 100 mg/dL if the child has other risk factors, per American Academy of Pediatrics guidance.
• Liver enzymes and CK: Evolocumab itself does not require routine liver-function or creatine-kinase monitoring, unlike statins. If the child is on a concurrent statin (common in HeFH management), the statin's monitoring schedule applies.
• Growth and development: No formal growth-monitoring requirement exists in the Repatha label, but in any child on a long-term injectable biologic, tracking height, weight, and pubertal development as part of routine well-child care is reasonable clinical practice.
• Injection-site rotation log: Keeping a simple written or app-based log of which site was used each administration helps prevent lipodystrophy and uneven drug absorption over time.

Talking With Your Child About Injections

Children between 10 and 12 years often have strong opinions about medical procedures. Involving them in the process rather than doing injections to them tends to improve adherence and reduce anxiety over time.

Practical strategies include:

• Let your child choose the injection site from the approved options.
• Allow your child to hold the used device (capped and safe) after injection, giving a sense of control over the process.
• Use a consistent routine: same time of day, same preparation steps in the same order.
• A vibrating tactile device placed near (not on) the injection site can reduce pain perception via gate-control mechanisms in children who are needle-sensitive.
• Acknowledge that the injection may hurt briefly without dismissing the sensation. Telling a child "this won't hurt" when it might builds distrust and worsens future anxiety.

If injection anxiety is severe enough to threaten adherence, ask for a referral to a pediatric psychologist with experience in medical procedure preparation. Cognitive-behavioral techniques reduce procedure-related distress in children and are worth the additional appointment.

Evidence Gaps and What We Do Not Yet Know

Honesty about what the data does not cover is a core part of this guide.

• Children under 10: No randomized evolocumab trial has enrolled children younger than 10. All use in this group is extrapolated from adolescent and adult pharmacokinetic data.
• Long-term pediatric outcomes: HAUSER-RCT ran for 24 weeks. Long-term cardiovascular outcome data in children treated with PCSK9 inhibitors do not yet exist. We know LDL-C goes down, and we reasonably expect that to translate to reduced cardiovascular events based on adult data, but this has not been demonstrated directly in a pediatric cohort.
• Sex-specific pediatric pharmacokinetics: No published analysis of evolocumab pharmacokinetics stratified by sex exists in children. In adults, body weight affects exposure, and girls and boys differ in adipose distribution and body composition during puberty, which could theoretically affect subcutaneous drug absorption. This has not been studied.
• Impact on puberty and hormonal development: No data. The prescriber should be asked to document that this has been considered in the monitoring plan.